These 5 Penny Stocks On Robinhood Are Anticipating Results This Week
When you talk to someone about penny stocks, you generally see two, very different responses. Typically for those who are either new to these low priced stocks or who’ve lost money in the past, they presume penny stocks & scams are one and the same.
However, this is just not the case. There are hundreds of cheap stocks that trade across numerous markets that have valid business models but unfortunately are valued much less than the Facebooks, Twitters, or even Pinterests of the world.
One of the industries to best show this has become the biotechnology industry. These companies are always working toward the next big thing to cure disease or improve quality of life. Yet they need to go through the proving ground of phase trials and supporting data.
[Read More] Top 10 Penny Stocks On Robinhood To Watch For November 2019
Now, thanks to Robinhood, penny stocks are becoming more and more accessible. Some may say that this platform has revolutionized the trading space as a whole. We’ve seen first-hand how some of the most established brokers online are beginning to offer a no-fee option for new users.
Penny Stocks To Watch On Robinhood This Week
Thanks to this, more people are beginning to trade penny stocks. But just because this is the case, it doesn’t mean Robinhood has dwindled. This platform has remained one of the more popular among younger traders. Furthermore, because penny stocks on Robinhood are restricted to NASDAQ and NYSE issuers, there’s a bit more information available.
That’s in comparison to OTC penny stocks. Regardless, we’re looking at a few companies that will be reporting data on recent programs. Some of them report over the weekend, others report this week. Depending on the outcomes, these data could make for interesting bearish or bullish catalysts.
Robinhood Penny Stocks to Watch #5: Lipocine Inc. (LPCN)
*Updated*
The first company on this list of penny stocks on Robinhood is Lipocine Inc. (LPCN Stock Report). This clinical-stage company has focused its attention on endocrine disorders. Lipocine has several therapies in its pipeline, making it relatively diverse. These include LPCN 1148, LPCN 1107, LPCN 1144, TLANDO, and TLANDO XR. Now, these may appear to have little meaning at this point in the article so let’s break some things down.
Heading into the week, the company is set for its Prescription Drug User Fee Act date or “PDUFA date.” If you’re unfamiliar with this term, it’s ok; let’s dive a little deeper. According to the FDA, this plays an important role in speeding up the drug approval process:
This was previously announced in May regarding the company’s TLANDO therapy. This is a testosterone replacement therapy for males who are deficient in endogenous testosterone. Furthermore, this is piggybacking off of the company’s previously filed and accepted New Drug Applications (NDA).
Read More
- Penny Stocks To Buy For Under $2; One Up 183% This Quarter
- The Best Penny Stocks To Watch Next Week?
- How Do I Buy Penny Stocks & Make Money?
Should this all be positive from the FDA, it could be a bullish catalyst for the company. On the flip side, if the response is negative then the bears could come out and play. In any case, we’ll see what happens as this date falls on the weekend and Monday would generally be the first we see signs of the outcome.
*UPDATE* as of 11/11/2019, Lipocine shares have confirmed what was said in the latter part of the above paragraph. The FDA rejected the company’s Tlando NDA. The FDA explained that the trial didn’t meet several endpoints for “maximal testosterone concentrations.”
Robinhood Penny Stocks to Watch #4: DURECT Corporation (DRRX)
One of the penny stocks we’ve discussed a few times in the past was DURECT Corporation (DRRX Stock Report). In fact, since our first article on DRRX stock (click here), we’ve seen shares skyrocket from under $1.70 to more than $2.40. But why is DRRX back in the spotlight this week?
As previously announced in October, DURECT presents data at The Liver Meeting 2019 this week. On November 12, the company will give an oral presentation, which follows up a poster presentation from November 10. Study results were actually selected to be included in the “Best of The Liver Meeting” slide presentation. The recently completed Phase 2a study was for its DUR-928, which is for patients with alcoholic hepatitis.
“These compelling data provide a strong rationale for continued development, and we plan to initiate a Phase 2b study for this difficult-to-treat and life-threatening condition next year,” said James E. Brown, President and Chief Executive Officer of DURECT in a press release.
Robinhood Penny Stocks to Watch #3: VBI Vaccines, Inc. (VBIV)
Early this week, VBI Vaccines (VBIV Stock Report) is another likely candidate as one of the penny stocks to watch on Robinhood. After bottoming out hard over the past few quarters, long-term investors are likely looking for some signs of positivity from the company.
As a commercial-stage company, VBI targets infectious disease and immune-oncology vaccines. In an abstract, the company was chosen for a “late-breaker” poster presentation at The Liver meeting this week.
Monday marks the day of its presentation of Phase-3 study data. This will showcase VBI’s double-blind Phase 3 results from its PROTECT study. Specifically, it goes over the outcome from over 1,600 patients who’ve received doses of the companies Sci-B-Vac compared to Engerix-B. Could this be the thing that triggers a move in VBIV stock for the better or is the next slide coming? Join the conversation on our social media.
Robinhood Penny Stocks to Watch #2: Mallinckrodt plc (MNK)
Another one of the penny stocks to watch since mid-October has been Mallinckrodt plc (MNK Stock Report). However, heading into the new week, there’s more to watch than just MNK stock, itself. This week the company will present data on its Phase 3 CONFIRM study at The Liver Meeting. The company’s terlipressin was tested on 300 adults with hepatorenal syndrome type 1. This disease impacts kidney function in certain individuals.
When it comes to Phase 3, these data sets represent a potential turning point for companies ultimately looking to commercialize a drug. Also keep in mind that based on the trial already, Mallinckrodt plans to submit its New Drug Application to the FDA in “early 2020.”
Could this be a precursor to what they expect to present at the meeting this week? In response to this, presenting author Florence Wong, MBBS, MD, FRACP, FRCPC, a hepatologist at Toronto General Hospital, and professor of Medicine at the University Of Toronto had some things to say.
“I am encouraged by the results of the CONFIRM trial of terlipressin, which, if approved, may make a difference in this difficult-to-treat patient population and I look forward to sharing these results for the first time at [The Liver Meeting].”
Robinhood Penny Stocks to Watch #1: Agile Therapeutics Inc. (AGRX)
Finally, Agile Therapeutics Inc. (AGRX Stock Report) rounds out this list of penny stocks Robinhood traders are likely watching this week. We’ve followed this company on PennyStocks.com in November and it has been explosive since that time. In fact, the first time we did this month, shares sat at 52-week lows below $0.40.
This healthcare company focuses on women’s medical needs. Originally, it became one of the best penny stocks to watch after reporting that its Twirla contraceptive patch received a favorable outcome from the FDA Advisory Committee Meeting.
Why has AGRX stock landed on the list this week? The FDA assigned a PDUFA goal date of November 16. Thought this is later in the week, this could be reason enough to make it a penny stock to watch. This event is for the completion of the FDA’s review of Twirla’s New Drug Application.
“We are very pleased that BRUDAC voted in favor of Twirla. We look forward to continuing our dialogue with the FDA about the important data presented today and working toward a potential approval of Twirla.”
Al Altomari, Chairman and Chief Executive Officer of Agile
Shares of the company have seen one of the most volatile periods in recent months. Even after hitting 52-week lows early in November, those focusing on this stock have seen it skyrocket to highs of nearly $3.00 a share. Based on the nature of the market, will AGRX once again give reason to add it to a penny stocks watch list this week?
